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Summary The role of bct-2 expression in solid tumours is as yet undefined. It was, therefore, the purpose of
this study to investigate expression of bc1-2 protein in 111 human breast carcinomas using immunohis-
tochemistry and the monoclonal antibody bc1-2 124. Expression was then compared with the established
indicators of prognosis and biological behaviour in malignant breast disease. No relationship could be
observed between bc1-2 and node status, tumour size, differentiation, type or age at excision. However, a
strong positive relationship was seen between bcl-2 and oestrogen receptor (ER), with 70 of 88 (80%)
bcl-2-positive tumours being ER positive also, compared with seven of 23 (30%) bcl-2-negative tumours being
ER positive (P<0.0001). The converse was found when bc1-2 was compared with epidermal growth factor
receptor (EGFR). A strong negative relationship was observed, with 26 of 88 (30%) bcl-2-positive tumours
being EGFR positive, compared with 16 of 23 (70%) bcl-2-negative tumours being EGFR positive
(P = 0.001), raising the possibility that bcl-2 is an ER-regulated gene. An inverse relationship was also found
between bc1-2 and the oncogenes c-erbB-2 and p53. Thus, loss of bcl-2 expression in breast cancer is associated
with a range of molecular markers of poor prognosis and may define part of an ER-negative, EGFR-positive
phenotype.
The bcl-2 proto-oncogene was first described as a result of
the chromosomal translocation t(14;18) seen in a large
number of follicular B-cell lines (Tsujimoto et al., 1985). The
result of this translocation juxtaposes the bcl-2 gene on
chromosome 18 with the immunoglobulin heavy-chain (IGH)
gene of chromosome 14 (Bakhshi et al., 1985; Cleary &
Sklar, 1985; Cleary et al., 1986; Tsujimoto & Croce, 1986),
Tsujimoto et al., 1987). This frequently results in the over-
expression of bcl-2 protein as a result of the marked
deregulation of the bcl-2-IGH fusion gene (Cleary et al.,
1986; Graninger et al., 1987; Chen-Leavy et al., 1989), which
confers affected lymphocytes with a resistance to apoptosis or
programmed cell death (Hockenbery et al., 1990). Normal
bcl-2 expression is associated with proliferative cells and cells
which have a need for longevity, such as stem cells, neurons
and memory B cells. In continuously renewed systems, such
as those found in the epithelium of the gut, skin and breast,
cells lose bcl-2 expression prior to apoptotic cell death. bcl-2
is often demonstrated in glandular cells in which regulation
of hyperplasia and involution is controlled by hormones and
growth factors (breast), complex differentiating epithelium
with long-lived stem cells (skin, intestine) and fully
differentiated long-lived non-cycling cells (neurons) (Nunez et
al., 1990).
bcl-2 is so far unique as a proto-oncogene in that it codes
for an inner mitochondrial membrane protein (Hockenbery
et al., 1990). The bcl-2 protein has a unique sequence with no
substantial homology with any other proto-oncogene pro-
ducts; it is lipophilic in character, suggesting that it is per-
haps a membrane-spanning protein (Cleary et al., 1986;
Tsujimoto & Croce, 1986). Its localisation suggests that it is
involved in some way with the metabolic functions of the
inner mitochondrial membrane site, i.e. oxidative phos-
phorylation and electron transport (Hockenbery et al., 1990).
However, bcl-2 protects against apoptosis even in cells with-
out mitochondria (Jacobson et al., 1993).
The importance of bcl-2 expression in solid tumours is not
defined, and it is not known whether there is any biological
difference in solid tumours retaining expression of bcl-2. It
has previously been noted that in normal breast epithelium
bcl-2 is expressed in all cells of large and small ducts,
although this observation was only in one premenopausal
woman (Hockenbery et al., 1991). It was, therefore, the
purpose of this study to investigate whether expression of
bcl-2 could be seen in malignant lesions of breast epithelium
and adjacent normal tissue, and whether retention or loss of
bcl-2 expression could be correlated with predictors of out-
come such as oestrogen receptor (Howell et al., 1984), epider-
mal growth factor receptor (Sainsbury et al., 1987), c-erbB-2
(Wright et al., 1989), p53 (Harris, 1992), tumour size,
differentiation, lymph node status and patient age at excision
(McGuire & Clark, 1992).
The relationship between bcl-2 and p53 is of particular
interest. In normal cells p53 is expressed at low levels and
plays a major role in cell cycle control. When stress-inducing
DNA damage occurs, its expression is increased and the cell
cycle is arrested. It is thought that p53 binds as a tetramer to
a specific DNA sequence, resulting in transcription of
growth-inhibitory genes. It is not uncommon for the cells of
developing tumours to undergo stress induced by anoxic
conditions or aneuploidy. This could also explain why p53
mutations occur later in tumour progression, when stress
would confer a selective advantage on cells with p53 muta-
tions (Vogelstein & Kinzler, 1992). p53 also has a normal
role in apoptosis, and mutations in p53 confer resistance to
apoptosis (Yonisch-Rouach et al., 1991; Shaw et al., 1992).
This loss of function of p53 would have a similar net effect
to the gain of function of bcl-2. Tumour cell numbers would
increase as a result of both unregulated proliferation and
resistance to cell death. An inverse relationship between bcl-2
protein expression and p53 has previously been described in
non-Hodgkin's lymphoma (Pezzella et al., 1992a). It would
therefore be of interest to determine whether this relationship
is also found in breast carcinoma.
Materials and methods
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Representative portions of III primary invasive breast car-
cinomas were snap frozen in liquid nitrogen within 30 min of136 R.D. LEEK et al.
surgical resection, and stored until required. Sections for light
microscopy were taken and processed using conventional
laboratory techniques. Histological classification and assess-
ment of differentiation was accomplished independently by
light microscopy prior to immunohistochemical staining.
Immunohistochemistry
bc1-2 protein, p53 and c-erbB-2 were stained immunohisto-
chemically using the mouse monoclonal antibodies bcl-2 124
(Pezzella et al., 1992b) (LRF Immunodiagnostics Unit,
Oxford), PAb 240 (Gannon et al., 1990) (ICRF) and NCL
CB 11 (Corbett et al., 1990) (Novocastra Laboratories, New-
castle upon Tyne) respectively. Frozen sections were used for
staining bcl-2 protein and p53, while paraffin sections were
used for c-erb-2 detection. bcl-2 124 and PAb 240 were used
as undiluted tissue culture supernatant, and NCL CB 11 was
used at a 1:40 dilution.
Frozen sections of 5 ,sm were cut using a cryostat, air dried
overnight at room temperature and then fixed for 10 min in
acetone at - 20°C and air dried. Paraffin sections were
dewaxed in xylene and rehydrated through graded alcohols.
Both frozen and paraffin sections were blocked with 10%
normal rabbit serum for 30 min before application of
primary antibody for 1 h. The alkaline phosphatase-anti-
alkaline phosphatase (APAAP) method (Cordell et al., 1984)
was then used to amplify the primary antibody signal; the
sections were incubated with rabbit anti-mouse antibody for
30 min, and then with mouse monoclonal APAAP for a
further 30 min. These two steps were then repeated once for
10min each, then the stain was developed with new fuchsin
substrate for 10 min, yielding an insoluble red reaction pro-
duct. The reaction was halted with distilled water. Following
counterstaining with Gill's haematoxylin for 15 s, the sections
were mounted in an aqueous mounting medium. The sections
were washed with Tris-buffered saline (TBS) pH 7.6 between
each step, and all steps were carried out at room
temperature.
Determination ofoestrogen receptor and epidermal growth
factor receptor levels
All procedures were performed at 0-4°C. Tumours were
pulverised in liquid nitrogen and further homogenised in a
ratio of 1:20 (w/v) in buffer (0.02 M HEPES, 0.00075 M
EDTA, 0.001 M benzamidine, 0.0005 M PMSF, 1 ,tg ml-l
ovomucoid, pH 7.4, at 20°C) using three 10-s bursts of a
Polytron homogeniser at setting 6. The homogenate was
centrifuged at 3,000 r.p.m. for 10min. The supernatant was
centrifuged at 37,000 r.p.m. for 40 min. The pellet (crude
membrane fraction) was resuspended in buffer and stored at
- 80°C until assayed for EGFR. The supernatant (cytosol)
was made 0.002 M with respect to dithiothreitol and assayed
using the method of Bradford (1976) with bovine serum
albumin (BSA) as standard.
ER content was determined on tumour specimens by the
dextran-coated charcoal method (EORTC Breast Cancer Co-
operative Group, 1980). Tumours with cytoplasmic oestrogen
receptors levels over 5 fmol per mg of protein were con-
sidered positive.
The EGFR level was determined by a method described
previously (Nicholson et al., 1988). Aliquots of membranes
(50-100.g of protein) were incubated for 1 h at 25°C with
['25I]EGF (final concentration 1 nM) in the presence and
absence of unlabelled EGF (final concentration 100 nM) to
correct for non-specific binding. Membranes were pelleted by
centrifuging at 14,000g for 7 min at 4°C, washed with ice-
cold phosphate-buffered saline (PBS) containing 0.2% BSA,
recentrifuged as above and counted in a Beckman Gamma
5500B spectrometer. Tumours with an EGFR level of over
20 fmol per mg of protein were considered positive.
Statistical analysis
To evaluate statistical significance the chi-square and Fisher
exact tests were applied as appropriate. A P-value of <0.05
was considered significant.
Results
Tissue distribution ofimmunochemical staining
Of the 111 specimens stained, 74 had normal epithelium
adjacent to areas of tumour. Of these, 72 (97%) were positive
for bcl-2 (Figure la). Also, in the seven specimens of benign
disease stained, both affected and normal epithelium was also
positive for bcl-2. However, in the areas of invasive tumour,
only 88 of the 111 tumours expressed bcl-2 (Figure Ic), 79%
of the total, leaving 23 tumours or 21% bcl-2 negative
(Figure ld). In addition, of the 88 positive tumours, 12 did
display some areas of focal loss of expression. Lymphocytes,
which always expressed bcl-2, and areas of adjacent normal
tissue were utilised as in-built positive controls in cases where
the tumour was found not to express bcl-2 (Figure lb).
Connective tissue fibroblasts did not express bcl-2 in any of
the specimens studied.
Forty-three of the 111 invasive tumours also contained
areas of in situ disease, which was assessed separately (Table
I). Of 38 patients with bct-2-positive invasive disease, 34
(90%) also had bcl-2-positive in situ areas. Of the five
patients with bcl-2-negative invasive disease, all were likewise
negative in their in situ areas (P= 0.0001).
Node status
In breast disease the single most powerful predictor of out-
come is axillary node status. Of our 111 patients, 108 have
had axillary node dissections and a comparison of the results
is shown in Table II. Sixty-two of 108 (57%) were found to
be node positive. Fifty-two of 85 (61%) bcl-2-positive
patients were node positive. Of the 23 bcl-2-negative patients,
ten (43%) were node positive (no significant difference:
P = 0.199).
Other clinicalparameters
Of the series of tumours stained for bcl-2, 107 had their size
at excision recorded. The average size of the 85 bcl-2-positive
tumours was 25 (± 1) mm compared with an average of 29
(± 2) mm in the 22 bcl-2-negative tumours. Similarly, no
difference could be seen in bcl-2 expression in tumours of
< 10 mm compared with those that were larger (P = 0.682).
Nor could any correlation be found between bcl-2 expression
and tumour type (P = 0.315 when comparing ductal car-
cinomas with all other types) or degree of differentiation
(P = 0.702). The prevalence of bcl-2 expression in the
tumours of pre- and post-menopausal women is roughly
similar, 76% in women of 50 and younger and 81% in
women over 50; no significant difference is evident (P=
0.681) (Table II).
Receptor status
All 111 patients in our series had accompanying ER and
EGFR status recorded. Breast carcinomas were considered
positive for ER if they contained > 5 fmol of ER per mg of
protein. Comparing bcl-2 expression with ER status using
this cut-off point, a close relationship of expression was
observed.
Seventy of 88 bcl-2-positive tumours (80%) were also ER
positive, whereas of the bcl-2-negative tumours only seven
out of 23 (30%) were positive for ER (P<0.0001) (Table
III).
Tumours containing >20 fmol of EGFR per mg of pro-
tein were considered positive for EGFR. Twenty-six out of
88 bcl-2-positive tumours were EGFR positive (30%), com-
pared with 16 out of 23 bcl-2-negative tumours (70%). This
was the converse of the findings for ER (P = 0.001) (Table
III).
Using ER and EGFR status, it is possible to divide breast
cancer patients into four distinct prognostic groups (Sain-
sbury et al., 1987). Patients with ER+/EGFR- tumours have
the best prognosis. Prognosis is poorer for patients with the
ER-/EGFR- followed by patients with ER+/EGFR+bcl-2 EXPRESSION IN BREAST CARCINOMA 137
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Figure 1 a, bcl-2-positive benign epithelium of normal duct (n) (bar = 100jsm). b, bcl-2-positive benign epithelium (n) and positive
lymphocytes (1) with negative tumour (t) (bar = 100gim). c, bcl-2-positive tumour (t) surrounded by negative connective tissue
(bar = 50gm). d, bcl-2-negative tumour (t) with positively stained lymphocytes (1) (bar = 50 im).
tumours; finally, ER-/EGFR+ tumours are associated with
the worst prognosis. Comparing these groups (shown in
Table IV), both ER-positive groups have the highest propor-
tion of bcl-2-positive tumours (93% and 86% respectively).
However, the most marked down-regulation of bcl-2 expres-
sion is in ER-negative tumours which are also EGFR
positive (38%) (P<0.0001 when compared with other three
groups combined), suggesting an inhibitory role for EGFR
on bcl-2 expression.
Table III Expression of oestrogen receptor, epidermal growth factor

















c-erbB-2 protein is another receptor in the EGFR family.
Expression of c-erbB-2 was rare in bcl-2-positive tumours
Table I bcl-2 expression in in situ areas ofinvasive breast carcinoma
(P = 0.0001)
bcl-2-positive bcl-2-negative














Table II Comparison ofbcl-2expression ininvasivebreastcarcinomawith nodestatus(P = 0.199), tumoursizeatexcision(P = 0.682), tumourtype
(P = 0.315), degree of differentiation (P = 0.702) and age at excision (P = 0.681)
Node status Size Tumour type Differentiation Age (years)
Mod-
Positive Negative < 10mm >10 mm Ductal Lobular Mixed Other Good erate Poor <50 >50
bcl-2-positive 52 33 8 77 61 14 9 4 8 30 23 28 56
invasive disease
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Table IV bcl-2 expression in receptor-defined prognostic groups
ER+/EGFR- ER-/EGFR- ER+/EGFR+ ER-/EGFR+
bcl-2-positive 52 10 18 8
invasive tumours
bcl-2-negative 4 3 3 13
invasive tumours
bcl-2 positive (%) 93 77 86 38
(only 4%, Table III). However, expression was markedly
higher in the bcl-2-negative tumours (32%) (P= 0.004).
When bcl-2 and p53 expression were compared, it was
apparent that an inverse relationship existed between the two
oncoproteins (Table III). One hundred tumours were stained
for both and it was found that only 27 out of 79 bcl-2-
expressing tumours also expressed p53 (34%); however, of
the 21 bcl-2-negative tumours, 15 were p53 positive (71%)
(P = 0.005).
Discussion
bcl-2 has been shown to confer resistance to apoptotic cell
death (Vaux et al., 1988). It is apparent that in normal breast
epithelium bcl-2 is nearly always expressed; this is also true
of benign breast disease. In the normal breast, a continuous
renewal system is in operation, which is partly controlled
hormonally. This process progresses at a much slower rate
than, for example, that seen in the gut. Other glandular
organs with slow cell turnover rates also show bcl-2 expres-
sion, for example the thyroid (Hockenbery et al., 1991).
Occasionally epithelial cells that had been shed into the
luminal space were negative for bcl-2. They had probably lost
bcl-2 expression and were now in the process of undergoing
apoptosis.
A tumour that is derived from breast epithelial cells might
also be expected to express bcl-2. Apoptosis is a feature
commonly seen in tumours, and in fact the ability to resist
apoptosis may seem to offer an advantage to a rapidly
growing tumour, by slowing down the cell loss rate.
We have observed that bcl-2 is expressed in 79% of
invasive breast carcinomas, and that this expression is
generally mirrored in adjacent in situ disease when it is
present. Since 97% of normal breast epithelium specimens,
91% of in situ cancer specimens and 79% of tumours express
bcl-2, it can be concluded that loss of bcl-2 expression, when
it occurs, is a relatively late event in the progression of the
disease. This is the converse of the observation of erbB-2,
which is present in situ and lost in invasive cancer (Barnes et
al., 1988). However, in a few cases, there is loss of bcl-2 from
in situ cancer but not from adjacent invasive cancer. The
explanation may be that in these cases the invasive element
has arisen from a different in situ component to that studied
in adjacent areas.
It has been suggested that p53 and bcl-2 have opposite
functions: that p53 is a death pathway gene (Yonisch-
Rouach et al., 1991; Shaw et al., 1992) and that bcl-2 is an
antidote to programmed cell death (Hockenbery et al., 1990).
Aberrations in either function could lead to extended survival
of neoplastic cells and the increased likelihood of mutational
aberrations in other oncogenes, such as those responsible for
growth and proliferation or tumour-suppressor genes. We
found that there is an inverse relationship between bcl-2 and
p53. It is possible that either one or the other is sufficient to
modify the apoptosis pathway in solid tumours.
It has been noticed previously that bcl-2 expression is
associated with glandular epithelium in which regulation of
hyperplasia and involution is achieved hormonally or by
growth factors. The breast is a prime example of such tissue,
with both oestrogen and epidermal growth factor playing
important roles in the regulation of breast epithelium.
Indeed, the levels of oestrogen receptor (ER) and epidermal
growth factor receptor (EGFR) are in themselves predictors
of prognosis, ER being associated with good prognosis
(Howell et al., 1984) and EGFR associated with poor prog-
nosis (Sainsbury et al., 1987). Eighty per cent of bcl-2-
positive tumours were also ER positive, compared with only
30% in the bcl-2-negative group. This raises the possibility
that bcl-2 could be an oestrogen-regulated protein. A similar
finding has been reported by Chan et al. (1993) in a series of
41 patients with breast carcinoma. Consistently, a negative
relationship was found between bcl-2 and EGFR and c-erbB-
2. Although bcl-2 expression was correlated with ER, it was
in the EGFR+/ER- group, rather than the EGFR-/ER-
group, that the inverse relationship was most marked. This
suggests that EGFR ligands may have a role in down-
regulation of bcl-2.
In conclusion, the normal biological mechanism of action
of bcl-2 is as yet unknown. It does appear, however, that it
may be under hormonal control, acting as a regulator of
cellular events until it is switched off. At this point in normal
tissue, apoptosis would occur. In neoplastic tissues the reduc-
tion in expression of bcl-2 may require alternative survival
pathways. If such cells are thereby relatively more resistant to
apoptosis, this may contribute to their resistance to therapy
and environmental stress, hence a poorer prognosis. Loss of
bcl-2 expression was associated with a range of other poor
prognostic markers including EGFR, c-erbB-2 and p53
positivity. Thus its role in breast cancer progression may
differ substantially from that seen in lymphoma, in which
activation by translocation occurs. bcl-2 is universally ex-
pressed in normal breast epithelium, and a subset of tumours
lose expression at a later stage in their progression; this
group is associated with the established molecular markers of
poor prognosis. However, whether bcl-2 expression will prove
to be an independent marker of prognosis in neoplastic
breast disease remains to be seen.
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